MSH2 and cancer: In a comparison, partly overlapping with the one conducted by Kratz et al., further empirical support is seen; of 4,574 children with cancer tested for MSH2 seven (0.15%, 7/4,574) carried a LoF variant in the gene (Supplementary Data 5–26), compared to 31 such carriers among 125,564 individuals in gnomAD (0.02%) (Fisher’s exact test, 7/4,574 vs. 31/125,564, OR = 6.2 [95% CI 2.3−14.3], p = 3.219e-4, Supplementary Data 34).